DEF: Lucid Diagnostics Inc. Announces Annual Meeting of Stockholders to Vote on Director Elections, Stock Issuance, and Accountant Ratification

Lucid Diagnostics Inc. will hold its annual meeting on June 18, 2025, to vote on director elections, approve a stock issuance related to convertible notes, and ratify the appointment of its accounting firm.

Summary

• Lucid Diagnostics Inc. is holding its annual meeting of stockholders on June 18, 2025, virtually.
• Stockholders will vote on three proposals: electing two Class A directors, approving the issuance of shares under the 2024 Convertible Notes, and ratifying the appointment of CBIZ CPAs as the independent accounting firm for the year ending December 31, 2025.
• The Board recommends voting FOR all three proposals.
• The record date for determining stockholders eligible to vote is April 22, 2025.
• The company uses the internet as the primary means of furnishing proxy materials to stockholders.
• As of the record date, there were 105,382,957 shares of common stock outstanding and 54,419 shares of preferred stock outstanding, convertible into 24,371,659 shares of common stock.
• In November 2024, the Company sold $21.975 million in principal amount of 2024 Convertible Notes in a private placement.
• As of March 31, 2025, an estimated 36,975,000 shares of our common stock were issuable upon conversion of, and in payment of interest on, the 2024 Convertible Notes.
• CBIZ CPAs acquired the attest business of Marcum LLP on November 1, 2024, and was appointed as the company's independent registered public accounting firm on April 23, 2025.
• The company is authorized to issue 300,000,000 shares of common stock and 20,000,000 shares of preferred stock.
• The Board is divided into three classes, with directors serving staggered three-year terms.

Sentiment

Score: 7

Explanation: The document is primarily factual and procedural, outlining the agenda for the annual meeting and seeking approval for routine corporate matters. The sentiment is neutral to slightly positive, as the company is actively managing its governance and financial obligations.

Positives

• The Board is actively seeking stockholder approval for key proposals, demonstrating a commitment to corporate governance.
• The company has secured $21.975 million in funding through the issuance of convertible notes, providing capital to pursue its business plan.
• The company has a management services agreement with PAVmed, which provides economies of scale and permits the Company to focus its infrastructure and resources on the pillars of its growth strategy.
• The company has a code of ethics that applies to all of its executive officers, directors and employees.

Negatives

• Approval of the Stock Issuance Proposal requires the affirmative vote of a majority of the shares of the Company's common stock represented in person or by proxy at the meeting and entitled to vote thereon.
• If the stockholders do not approve this proposal, the Company will be unable to issue in excess of 19.99% of the Company's outstanding shares of common stock as of immediately prior to the transactions.
• The issuance of shares pursuant to the 2024 Convertible Notes will have a dilutive effect on the existing stockholders, including on the voting power and economic rights of the existing stockholders, and may result in a decline in the price of the Company's common stock or in greater price volatility.
• The company is dependent on PAVmed for management and other services, which could create conflicts of interest.

Risks

• Failure to obtain stockholder approval for the stock issuance proposal could limit the company's ability to convert the 2024 Convertible Notes, potentially requiring refinancing or repayment in cash, which would deplete available funds.
• The company's dependence on PAVmed for management services and potential conflicts of interest could negatively impact decision-making and strategic direction.
• The issuance of additional shares upon conversion of the 2024 Convertible Notes will dilute existing stockholders' ownership and could negatively impact the stock price.
• The company is subject to certain covenants under the 2024 Convertible Notes, including a financial covenant requiring that the amount of its available cash equal or exceed $5.0 million at all times that at least 25% of the principal amount of 2024 Convertible Notes issued are outstanding.

Future Outlook

The company's ability to successfully implement its business plans and ultimately generate value for its stockholders is dependent upon its ability to raise capital and satisfy its ongoing business needs.

Management Comments

• The Board has determined that the ability to issue shares of the Company's common stock to the holders of 2024 Convertible Notes is in the best interests of the Company and its stockholders.

Industry Context

The document relates to corporate governance and financial matters typical for a publicly traded company, including director elections, auditor ratification, and financing activities. The company's focus on medical diagnostics places it within the healthcare technology sector, where securing funding and maintaining regulatory compliance are critical.

Comparison to Industry Standards

• The structure of Lucid Diagnostics' board, with staggered terms and independent directors, aligns with common corporate governance practices among publicly traded companies in the US.
• The engagement of an independent auditor and the establishment of an audit committee are standard practices to ensure financial transparency and compliance.
• The use of convertible notes for financing is a common strategy for companies, particularly in the biotech and medical device industries, to raise capital without immediate dilution.
• Comparable companies in the medical diagnostics space, such as Exact Sciences (EXAS) and Hologic (HOLX), also rely on a mix of equity and debt financing to fund their operations and growth initiatives.
• The compensation structure for Lucid Diagnostics' executives, including base salary, bonus potential, and equity awards, is consistent with industry norms for similarly sized companies.

Related Party Transactions

• The company has a management services agreement with PAVmed, its parent company, for various management, technical, and administrative services.
• The company has a payroll and benefit expense reimbursement agreement with PAVmed.
• PAVmed assigned certain patent rights to the Company related to the EsoCheck device in consideration of a $350,000 assignment fee.

Stakeholder Impact

• Stockholders will have the opportunity to vote on key proposals that will impact the company's governance and financial structure.
• Employees may be affected by changes in management or compensation policies.
• The company's ability to secure funding and manage its operations will impact its ability to deliver products and services to customers.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its annual meeting on June 18, 2025.
• The company will continue to seek stockholder approval of the stock issuance proposal until it obtains such approval.

Key Dates

Keywords

annual meeting, proxy statement, stock issuance, convertible notes, director election, accountant ratification, CBIZ CPAs, Lucid Diagnostics, PAVmed, corporate governance